Filing Details
- Accession Number:
- 0001209191-21-032476
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-05-13 19:33:36
- Reporting Period:
- 2021-05-12
- Accepted Time:
- 2021-05-13 19:33:36
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1770787 | 10X Genomics Inc. | TXG | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1246406 | Bradford Crutchfield | C/O 10X Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton CA 94588 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2021-05-12 | 17,000 | $1.16 | 51,608 | No | 4 | M | Direct | |
Class A Common Stock | Disposition | 2021-05-12 | 5,123 | $133.86 | 46,485 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2021-05-12 | 7,875 | $134.70 | 38,610 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2021-05-12 | 2,702 | $135.74 | 35,908 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2021-05-12 | 1,200 | $136.80 | 34,708 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2021-05-12 | 100 | $137.57 | 34,608 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Class A Common Stock | Stock Option (right to buy) | Disposition | 2021-05-12 | 17,000 | $0.00 | 17,000 | $1.16 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
545,000 | 2027-02-03 | No | 4 | M | Direct |
Footnotes
- The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- This transaction was executed in multiple trades at prices ranging from $133.33 to $134.32. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $134.34 to $135.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $135.38 to $136.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $136.44 to $137.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This option, originally for 800,000 shares, of which 255,000 shares have been exercised, vested as to one-fourth of the shares on February 2, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.